Inovio Pharmaceuticals Inc vs JPMorgan Ultra Short Income ETF — how do they compare? Inovio Pharmaceuticals Inc trades at $0.77 (market cap $78.55M), while JPMorgan Ultra Short Income ETF trades at $50.47. The key difference: JPMorgan Ultra Short Income ETF is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| INO | JPST | |
|---|---|---|
Market Cap | $78.55M | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $2.87 | $50.78 |
52-Week Low | $0.66 | $50.40 |
Enterprise Value | $49.56M | — |
Signals from Pluang's Aura AI — not financial advice
INO trades at $0.772, up 4.83% in the last 24 hours, but technical indicators signal a bearish trend. The company shows minimal revenue of $65,340 in 2025 with a net loss of $84.95 million, though it has beaten EPS estimates in recent quarters. Key developments include an upcoming Q2 2026 earnings report on August 12, 2026, and a pending FDA decision on INO-3107 by October 30, 2026.
The outlook hinges on FDA approval of INO-3107, with a consensus price target of $3.25 implying significant upside. However, high cash burn, negative margins, and legal scrutiny pose substantial risks. Investors should weigh the binary event against persistent financial challenges.
JPST, the JPMorgan Ultra-Short Income ETF, trades at $50.465, up 0.05% daily, with a bearish technical signal driven by moving averages. The fund focuses on high-quality, short-term bonds, offering a cash alternative with consistent dividends, including recent $0.17 payouts. Institutional holdings have increased, as seen in 13F filings from Financial Management Professionals Inc. and Ashton Thomas Securities LLC in Q2 2026, indicating steady investor interest amid a rising rate environment.
The outlook for JPST is stable, benefiting from its low-risk profile in volatile markets, but faces headwinds from potential Fed rate hikes that could pressure short-term bond yields. Risks include interest rate sensitivity and inflation concerns, yet it remains a core holding for conservative investors seeking yield with minimal volatility.
Trailing returns across standard periods
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →JPST is an actively managed ETF that invests in short-term, investment-grade fixed income securities. It aims to provide current income and capital preservation while maintaining high liquidity.
Read more on JPST →